Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Will #Cures2015 Fix Twitter Promotion?

This article was originally published in The Pink Sheet Daily

Executive Summary

House 21st Century Cures discussion draft would adjust FDA promotion regulations for Twitter, requiring that information communicated through hyperlink be considered part of the original post.

You may also be interested in...

House Trims 21st Century Cures Fat: Draft Bill Loses Half Its Weight

New discussion draft drops controversial exclusivity extensions and some other lesser-known ideas that may have benefited FDA and sponsors, but some placeholders still need to be filled.

FDA Lull In Rx Promotion Citations Continues; Guidances May Be Bigger Priority

Even with recent letters, Office of Prescription Drug Promotion’s slow pace continues from 2014’s record low.

Antibiotics Top List Of New Exclusivity Benefits In Draft Cures Legislation

Sponsors could transfer or sell some QIDP exclusivity to other products under draft bill, which also offers new exclusivity perks for orphan drugs, 505(b)(2) applications, ANDAs and biosimilars – but GPhA isn’t happy.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts